DME

Three extra lines on an eye chart.
That may not seem like much at first glance (!), but those lines represent a significant step forward in the treatment of a form of diabetic retinopathy known as diabetic macular edema (DME).
In groundbreaking news this week, the Food and Drug Administration cleared the first drug of its kind to treat DME for people with diabetes, called Lucentis from California-based Genentech.
The FDA noted that this drug…